RWM
PRME icon

Raffa Wealth Management’s Prime Medicine PRME Stock Holding History

Raffa Wealth Management’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-250
Closed -$730 – 1117
2024
Q4 		$730 Buy
+250
New +$878 ﹤0.01% 934

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return

Raffa Wealth Management's PRME Position: Q1 2025 in Review

Raffa Wealth Management sold out of Prime Medicine (PRME) in Q1 2025, closing a stake of 250 shares — an estimated $730 sold.

Raffa Wealth Management first reported a position in PRME in Q4 2024 and held it in 1 quarter. The position peaked at $730 in Q4 2024. 125 funds tracked by Wall St. Rank hold PRME as of Q1 2025.

  • Raffa Wealth Management reported no remaining Prime Medicine position as of Q1 2025 after selling out during the quarter.
  • Raffa Wealth Management sold 250 Prime Medicine shares in Q1 2025, an estimated $730.
  • Raffa Wealth Management first reported a position in Prime Medicine in Q4 2024 and held it in 1 quarter.
  • Raffa Wealth Management's Prime Medicine position peaked at $730 in Q4 2024.
  • 125 funds tracked by Wall St. Rank held Prime Medicine as of Q1 2025.

Based on Raffa Wealth Management's 13F filing for Q1 2025, filed 27 Jul 2026.